Price Chart


Price Chart

Profile

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It develops a novel, fully human monoclonal antibody, IMVT-1401, which selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded on July 6, 2018 and is headquartered in Durham, NC.
URL http://www.immunovant.com
Investor Relations URL https://www.immunovant.com/investors
HQ State/Province North Carolina
Sector Health Care
Industry Biotechnology
Next Earnings Release Aug. 10, 2026 (est.)
Last Earnings Release May. 20, 2026
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It develops a novel, fully human monoclonal antibody, IMVT-1401, which selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded on July 6, 2018 and is headquartered in Durham, NC.
URL http://www.immunovant.com
Investor Relations URL https://www.immunovant.com/investors
HQ State/Province North Carolina
Sector Health Care
Industry Biotechnology
Next Earnings Release Aug. 10, 2026 (est.)
Last Earnings Release May. 20, 2026
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A